BioNTech to Host First Edition of Innovation Series on Diversified Pipeline, Latest Technology Innovations

Rhea-AI Summary

BioNTech will host its first Innovation Series virtual event on June 29, 2022, at 8:00 a.m. EDT. This event aims to offer insights into the company's clinical advancements and technological innovations. Investors and the public can register for a listen-only webcast. Attendees can access the presentation and audio via a provided link, with the platform opening ten minutes before the event. A replay will be accessible for 30 days post-event. BioNTech specializes in pioneering therapies for cancer and infectious diseases, leveraging mRNA technology and global collaborations.

MAINZ, Germany, June 20, 2022 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the "Company”) will host the first edition of the Company’s Innovation Series on Wednesday, June 29^th, 2022. The virtual event will provide an update on BioNTech’s clinical progress across its pipeline and provide a deep-dive on scientific and technology innovation from its proprietary research engine.

Investors and the interested public are invited to join a webcast with investment analysts at 8:00 a.m. EDT (2:00 p.m. CEST). Online participation will be listen-only. To listen to the webcast, you will first need to register at the following link. You will then be able to access the slide presentation and audio of the webcast via this link and log in using the same email address you used to register. The platform will open ten minutes prior to the start of the event.

A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit www.BioNTech.de.

CONTACTS

Investor Relations
Sylke Maas, Ph.D.
VP Investor Relations & Strategy
Tel: +49 (0)6131 9084 1074
E-mail: Investors@biontech.de 

Media Relations
Jasmina Alatovic
VP Corporate Communications
E-mail: Media@biontech.de

FAQ

What is the date of BioNTech's first Innovation Series event?

BioNTech's first Innovation Series event is scheduled for June 29, 2022.

What time does the BioNTech webcast start?

The BioNTech webcast will start at 8:00 a.m. EDT (2:00 p.m. CEST).

How can I participate in BioNTech's Innovation Series webcast?

You can participate by registering through the link provided in the press release to access the listen-only webcast.

Will there be a replay of BioNTech's webcast available?

Yes, a replay of the webcast will be available shortly after the event and archived for 30 days.

What is the focus of the BioNTech Innovation Series event?

The focus will be on BioNTech's clinical progress and scientific innovations from their research engine.